Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Optimizing Response in Crohn's Disease Patients Who Have Insufficient Initial Response or Who Have Loss of Successful Response to Certolizumab Pegol (Cimzia) Induction Therapy

NCT01024647 is registered in ClinicalTrials.gov with Atlanta Gastroenterology Associates as lead sponsor.

NCT NCT01024647
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01024647 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Optimizing Response in Crohn's Disease Patients Who Have Insufficient Initial Response or Who Have Loss of Successful Response to Certolizumab Pegol (Cimzia) Induction Therapy
Lead sponsor
Atlanta Gastroenterology Associates
Phase
Phase 4
Overall status
Unknown status
Start date
December 31, 2009
Completion date
May 31, 2013
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease